Ian Estepan | Senior Vice President, Chief of Staff and Corporate Affairs |
Douglas Ingram | President and Chief Executive Officer |
Sandy Mahatme | Executive Vice President, Chief Financial Officer and Chief Business Officer |
Bo Cumbo | Executive Vice President and Chief Commercial Officer |
Louise Rodino-Klapac | Senior Vice President, Gene Therapy |
Gilmore O'Neill | Executive Vice President, R&D and Chief Medical Officer |
Michael Triplett | President and Chief Executive Officer, Myonexus Therapeutics, Inc. |
Alethia Young | Cantor Fitzgerald & Co. |
Ritu Baral | Cowen & Co, LLC |
Brian Abrahams | RBC Capital Markets |
Tazeen Ahmad | Bank of America Merrill Lynch |
Maxwell Skor | Morgan Stanley |
Debjit Chattopadhyay | H.C. Wainwright & Co., LLC |
Christopher Marai | Nomura Holdings, Inc. |
Mark Connolly | Credit Suisse |
Gena Wang | Barclays plc |
Brian Skorney | Robert W. Baird & Co. |
Ross Weinreb | Goldman Sachs |
Vincent Chen | Sanford C. Bernstein & Co., LLC |
Danielle Brill | Piper Jaffray |
Shawn Egan | Citigroup Inc. |
Tessa Romero | J.P. Morgan Chase & Co. |
Liisa Bayko | JMP Securities LLC |
Yun Zhong | Janney Montgomery Scott LLC |
Myles Minter | William Blair & Company |
Timothy Chiang | BTIG LLC |
Dae Gon Ha | SVB Leerink LLC |
Good day, ladies and gentlemen, and welcome to the Sarepta Therapeutics First Quarter 2019 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. [Operator Instructions] As a reminder, today's program is being recorded. And I would like to introduce your host for today's program, Ian Estepan, Senior Vice President, Chief of Staff and Corporate Affairs.